Breast cancers with somatic or germline BRCA 1/2 mutations may not be as responsive to checkpoint inhibitors as previously thought.
The FDA has accepted and set action dates for the luspatercept (Celgene and Acceleron) Biologic License Application.
Top news of the day from across the health care landscape.
Galcanezumab-gnlm (Emgality, Eli Lilly) is the first calcitonin gene-related peptide antibody approved for both migraine and episodic cluster headache in adults.
Popular brand-name prescription drugs have seen substantial price increases over the past 6 years, a trend that is likely to continue.
Top news of the day from across the health care landscape.
The National Association of Specialty Pharmacy has named Andy Slavitt, former Center for Medicare and Medicaid Services acting administrator, as the second keynote speaker for their seventh annual meeting.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.